scholarly journals Blastic Phase

2020 ◽  
Author(s):  
Keyword(s):  
Blastic Phase

Emergence of myeloid stem cell line from T-lymphoid blastic phase of chronic myeloid leukemia in culture

1992 ◽  
Vol 16 (5) ◽  
pp. 521-527 ◽  
Author(s):  
Anwar N. Mohamed ◽  
Mitchell R. Smith ◽  
Ayad Al-Katib ◽  
Sandra R. Wolman
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukemia ◽  
Cell Line ◽  
Myeloid Leukemia ◽  
Stem Cell Line ◽  
Blastic Phase

Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia

2016 ◽  
Vol 16 ◽  
pp. S82-S85 ◽  
Author(s):  
Jorge Luis Ángeles-Velázquez ◽  
Rafael Hurtado-Monroy ◽  
Pablo Vargas-Viveros ◽  
Silvia Carrillo-Muñoz ◽  
Myrna Candelaria-Hernández
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Philadelphia Chromosome ◽  
Phase Development ◽  
Blastic Phase ◽  
Philadelphia Chromosome Positive

A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia.

1991 ◽  
Vol 9 (1) ◽  
pp. 39-43 ◽  
Author(s):  
J A Martínez ◽  
G Martín ◽  
G F Sanz ◽  
A Sempere ◽  
I Jarque ◽  
...  
Keyword(s):  
Continuous Infusion ◽  
Myelogenous Leukemia ◽  
First Line ◽  
Platinum Drug ◽  
Treatment Regimens ◽  
Blastic Phase ◽  
Severe Infections ◽  
First Relapse ◽  
Acute Nonlymphoblastic Leukemia ◽  
Adult Leukemia

Carboplatin (CBDCA) is a second-generation platinum drug that has been shown to be useful when used as a continuous infusion in treatment of refractory adult leukemia. We report on the effectiveness of continuous infusion CBDCA, 300 mg/m2/d x 5 days, as evaluated in nine patients with secondary acute nonlymphocytic leukemia (ANLL) (seven previous myelodysplastic syndrome and two treatment-associated ANLL), three ANLL patients in first relapse, six refractory ANLL, and nine patients with blastic phase of chronic myelogenous leukemia (BP-CML). All patients were considered assessable. The response rate was 44% (eight complete remissions [CRs], four partial remissions [PRs]). Median duration of postchemotherapy neutropenia was 36 days (range, 18 to 45). Therapy was well tolerated, and toxicity was mainly hematologic and nondose-limiting. Despite prolonged neutropenia, severe infections were rarely seen, and most patients were managed as outpatients. Twelve patients had nausea and vomiting, two had symptomatic hypomagnesemia, and one patient showed reversible ototoxicity. Because of substantial antileukemic activity and unusual extrahematologic toxicity, CBDCA appears to be an effective second-line agent in the treatment of ANLL and should be considered for upgrading to first-line treatment regimens.

scholarly journals Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia

Blood ◽  
2002 ◽  
Vol 100 (5) ◽  
pp. 1590-1595 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Susan O'Brien ◽  
Jorge E. Cortes ◽  
Sergio A. Giralt ◽  
Mary Beth Rios ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Imatinib Mesylate ◽  
Allogeneic Stem Cell Transplantation ◽  
Response Rate ◽  
Chronic Phase ◽  
Complete Response ◽  
Cytogenetic Response ◽  
Myelogenous Leukemia ◽  
Blastic Phase

Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT) received imatinib mesylate (400-1000 mg/d). Disease was in chronic phase in 5 patients, accelerated in 15, and blastic in 8 (7 medullary, 1 extramedullary); median time from transplantation to relapse was 9 months (range, 1-137 months). Thirteen patients had undergone salvage donor lymphocyte infusion (DLI) (median time from DLI to imatinib mesylate therapy, 4 months [range, 2-39 months]). The overall response rate was 79% (22 of 28 patients); the complete hematologic response (CHR) rate was 74% (17 of 23 patients), and the cytogenetic response rate was 58% (15 of 26 patients; complete response in 9 [35%] patients). CHR rates were 100% for chronic phase, 83% for accelerated phase, and 43% for blastic phase. The patient with extramedullary blastic disease achieved complete response. Cytogenetic response rates were 63% (12 of 19 patients) for chronic or accelerated phases (complete cytogenetic response in 8) and 43% for blastic phase (3 of 7 patients). At median follow-up of 15 months, 19 patients were alive, 9 with no evidence of disease. The 1-year estimated survival rate was 74%. Five patients had recurrence of grade 3 (3 patients) or grades 1 to 2 (2 patients) graft-versus-host disease (GVHD). Severe granulocytopenia developed in 43% of patients and thrombocytopenia in 27%; both conditions reversed with dose adjustments of imatinib mesylate. We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD.

scholarly journals Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy

Blood ◽  
1976 ◽  
Vol 47 (6) ◽  
pp. 1003-1009 ◽  
Author(s):  
GP Canellos ◽  
VT DeVita ◽  
J Whang-Peng ◽  
BA Chabner ◽  
PS Schein ◽  
...  
Keyword(s):  
Complete Remission ◽  
Cytosine Arabinoside ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Blast Cell ◽  
Response To Therapy ◽  
Chronic Granulocytic Leukemia ◽  
Blastic Phase ◽  
Response To Chemotherapy ◽  
Granulocytic Leukemia

Abstract Thirty-two patients in the blastic phase of Philadelphia chromosome- positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine--prednisone (19 patients) was compared with cytosine arabinoside--6-thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine--prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine-- prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside--6-thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1--2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine-- prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.

Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia

2001 ◽  
Vol 19 (3) ◽  
pp. 762-771 ◽  
Author(s):  
Francis J. Giles ◽  
Jorge E. Cortes ◽  
Sharyn D. Baker ◽  
Deborah A. Thomas ◽  
Susan O’Brien ◽  
...  
Keyword(s):  
Dose Range ◽  
Chronic Phase ◽  
Pharmacokinetic Profile ◽  
Hematologic Malignancies ◽  
Nucleoside Analog ◽  
Myelogenous Leukemia ◽  
Blastic Phase ◽  
Starting Dose ◽  
Hand Foot Syndrome ◽  
Pharmacokinetic Behavior

PURPOSE: To investigate the toxicity profile, activity, and pharmacokinetics of a novel l-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia. PATIENTS AND METHODS: Patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was given as an intravenous infusion over 30 minutes daily for 5 days. The starting dose was 0.72 mg/m2/d (3.6 mg/m2/course). Courses were given every 3 to 4 weeks according to toxicity and antileukemic efficacy. The dose was escalated by 50% until grade 2 toxicity was observed, and then by 30% to 35% until the dose-limiting toxicity (DLT) was defined. RESULTS: Forty-two patients (AML: 31 patients; MDS: six patients [five MDS + one CMML]; ALL: four patients; CML-BP: one patient) were treated. Median age was 61 years (range, 23 to 79 years), and 29 patients were males. Stomatitis and hand-foot syndrome were the DLTs. The MTD was defined as 8 mg/m2/d. The pharmacokinetic behavior of troxacitabine is linear over the dose range of 0.72 to 10.0 m/m2. Approximately 69% of troxacitabine was excreted as unchanged drug in the urine. Marrow hypoplasia occurred between days 14 and 28 in 73% of AML patients. Three complete remissions and one partial remission were observed in 30 assessable AML patients. One MDS patient achieved a hematologic improvement. A patient with CML-BP achieved a return to chronic phase disease. CONCLUSION: Troxacitabine has a unique metabolic and pharmacokinetic profile and significant antileukemic activity. DLTs were stomatitis and hand-foot syndrome. Troxacitabine merits further study in hematologic malignancies.

Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG)

2000 ◽  
Vol 64 (3) ◽  
pp. 182-187 ◽  
Author(s):  
A. Tedeschi ◽  
M. Montillo ◽  
F. Ferrara ◽  
A. Nosari ◽  
G. Mele ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Cytosine Arabinoside ◽  
Myeloid Leukemia ◽  
Blastic Phase
Sign in / Sign up

Export Citation Format

Share Document